Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Inflammatory Myopathy.

Mastaglia1, Phillips, Zilko

  • 1Departments of Medicine, Neurology, and Clinical Immunology, Australian Neuromuscular Research Institute, 4th Floor, G Block, Queen Elizabeth II Medical Centre, Perth, Australia 6009.

Current Treatment Options in Neurology
|November 30, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naïve patients starting cART after January 1, 2000.

HIV clinical trials·2007
Same author

Isothermal Adsorption of Aflatoxin B(1) on HSCAS Clay.

Journal of agricultural and food chemistry·2001
Same author

9:15-9:30. Use of a Spherical 3-D Blob Analysis Program as a Method of Determination of Standardized Uptake Value (SUV) for Following Tumor Response to Chemotherapeutic Agents (CTA).

Clinical positron imaging : official journal of the Institute for Clinical P.E.T·2001
Same author

The function of dynamic grouping in vision.

Trends in cognitive sciences·2000
Same author

Technical appendix

JAMA·2000
Same author

AAEM news and comments

Muscle & nerve·2000
Same journal

Visual Impairment and Driving in Older Adults: A Narrative Review.

Current treatment options in neurology·2026
Same journal

Non-Cognitive Symptoms in Alzheimer's Disease and Their Likely Impact on Patient Outcomes. A Scoping Review.

Current treatment options in neurology·2026
Same journal

Update on the Treatment of Autonomic Disorders.

Current treatment options in neurology·2025
Same journal

Primary Progressive Aphasia Treatment: Current Treatment Options in Neurology Article Topic: Management of Primary Progressive Aphasia.

Current treatment options in neurology·2025
Same journal

Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).

Current treatment options in neurology·2025
Same journal

Diagnosis and Management of Progressive Corticobasal Syndrome.

Current treatment options in neurology·2025
See all related articles

For polymyositis and dermatomyositis, prednisone is the initial treatment, with immunosuppressants added for inadequate control. Inclusion body myositis requires a trial of prednisone, potentially with other agents.

Area of Science:

  • Rheumatology
  • Immunology
  • Neurology

Background:

  • Polymyositis and dermatomyositis are inflammatory myopathies.
  • Inclusion body myositis is a distinct condition with different treatment responses.

Purpose of the Study:

  • To outline current treatment strategies for polymyositis, dermatomyositis, and inclusion body myositis.
  • To guide therapeutic decisions based on disease characteristics and patient response.

Main Methods:

  • Initial treatment with prednisone (1 mg/kg/d) for 4–6 weeks.
  • Tapering prednisone to alternate-day regimen for at least 12 months.
  • Concomitant use of methotrexate or azathioprine for inadequate control.
  • Intravenous immunoglobulin for specific indications (immunodeficiency, intolerance, deterioration, severe relapses).

Related Experiment Videos

  • Cyclosporine or cyclophosphamide for resistant disease.
  • 3–6 month trial of prednisone, with or without methotrexate/azathioprine, for inclusion body myositis.

    • Main Results:

    • Prednisone effectively manages polymyositis and dermatomyositis initially.
    • Early introduction of immunosuppressants allows faster prednisone dose reduction and fewer side effects.
    • Intravenous immunoglobulin and other agents offer options for refractory or specific cases.
    • Inclusion body myositis shows variable response, necessitating a trial of immunosuppressive therapy.

    Conclusions:

    • A stepwise approach combining corticosteroids and immunosuppressants is crucial for managing inflammatory myopathies.
    • Tailoring treatment to individual patient needs and disease subtype optimizes outcomes.
    • Careful monitoring and dose adjustment are essential for long-term management and minimizing adverse effects.